1704P Potential surrogate endpoints for overall survival (OS) in immunotherapy (IO)-treated metastatic renal cell carcinoma (mRCC): An International Metastatic Database Consortium (IMDC) study
Saliby R, Xie W, Wells J, Saad E, Eid M, Semaan K, Labaki C, Ferrier E, Zarba M, Ebrahimi H, Rodriguez C, Ruiz J, Powles T, Wood L, De Velasco Oria G, Takemura K, Braun D, Heng D, Choueiri T. 1704P Potential surrogate endpoints for overall survival (OS) in immunotherapy (IO)-treated metastatic renal cell carcinoma (mRCC): An International Metastatic Database Consortium (IMDC) study. Annals Of Oncology 2024, 35: s1021-s1022. DOI: 10.1016/j.annonc.2024.08.1797.Peer-Reviewed Original Research